Patient description: A 3-day-old Asian female infant presents with jaundice that started a day ago. She was born at 38w3d of gestation, after an uncomplicated pregnancy. The family history is unremarkable. The baby is breastfed. Vital signs are reported as: axillary temperature: 36.3°C, heart rate: 154 beats/min, respiratory rate: 37 breaths/min, and blood pressure: 65/33 mm Hg. Her weight is 3.2 kg, length is 53 cm, and head circumference 36 cm. Her sclera are yellow and her body is icteric. No murmurs or any other abnormalities are detected in the heart and lung auscultation. Her liver and spleen are normal on palpation. Laboratory results are as follows: Serum total bilirubin: 21.02 mg/dL Direct bilirubin of 2.04 mg/dL AST: 37 U/L ALT: 20 U/L GGT: 745 U/L Alkaline phosphatase: 531 U/L Creatinine: 0.3 mg/dL Urea: 29 mg/dL Na: 147 mEq/L K: 4.5 mEq/L CRP: 3 mg/L Complete blood cell count within the normal range. She is diagnosed with uncomplicated neonatal jaundice that may require phototherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatocellular Cancer In this acute dose-finding section of the study, we will enroll patients with HCC and cirrhosis Both male and female patients 18 years of age or older will be eligible Patients with cancer must have a Karnofsky performance rating of at least 50% Patients must have HCC and cirrhosis that is not amenable to current therapies including liver resection, tumor ablation, or liver transplant Patients must be mentally alert and able to give informed consent Female patients who are menopausal, or of childbearing age who are surgically sterile or practicing birth control (chemical or mechanical) are eligible All females of childbearing potential must have a serum pregnancy test upon entry into the study and must take precautions to not become pregnant during the study (from the time of enrollment until 1 week after the infusion of OGF). No corticosteroid or narcotic therapy 24 hrs prior to infusion Volunteers must refrain from alcoholic beverages for 24 hours before, and 24 hours after, the day of infusion If patients have received sorafenib, at least 4 weeks must pass from the last dose At least four weeks must pass from significant surgery and the subject must be physically recovered  Patients with asthma, chronic obstructive pulmonary disease, unstable cardiovascular diseases (congestive heart failure, symptoms of coronary artery disease, cardiac arrhythmias, poorly controlled hypertension, have suffered a myocardial infarction in the preceding year or have an abnormal EKG) will not be allowed Patients with poorly controlled diabetes, seizure disorders, primary central nervous system (CNS) tumors or known brain metastases are excluded A clinical judgment will be made based on the other and performance status as to the patient's ability to tolerate therapy Serum total bilirubin and international normalized ratio (INR) will be used as markers of liver function in the as defined in Table 1 (see below) Pregnant or nursing women are not eligible Patients requiring antibiotics in the preceding week for a serious infection are not eligible Volunteers may have on the morning of the study one 8 ounce glass of water or juice and toast EKG and laboratory tests will be reviewed to evaluate whether any are met